Showing results (41-50 of 49) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Cornea|January 29, 2020
Contact Lenses and Infectious Keratitis: From a Case-Control Study to a Computation of the Risk for WearersArnaud Sauer, Mathieu Greth, Jonathan Letsch, et al.Orphanet Journal of Rare Diseases|April 12, 2018
Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins)Saskia Ingen-Housz-Oro, Tu-Anh Duong, Benoit Bensaid, et al.American Journal of Ophthalmology|February 16, 2022
Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 PatientsGeorgina Maalouf, Anaïs Andrillon, Mathilde Leclercq, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|May 27, 2026
Tocilizumab for severe and refractory mucous membrane pemphigoidBillal Tedbirt, Maud Maho-Vaillant, Julie Gueudry, et al.Ophthalmology|May 21, 2025
Comparative effectiveness of intravenous versus subcutaneous tocilizumab for refractory uveitis: a retrospective analysisMathilde Leclercq, Robin Jacquot, Camille Charbonnier, et al.Arthritis & Rheumatology (Hoboken, N.J.)|March 26, 2016
Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis NetworkHélène Vallet, Pascal Seve, Lucie Biard, et al.Orphanet Journal of Rare Diseases|March 11, 2023
Ocular sequelae of epidermal necrolysis: French national audit of practices, literature review and proposed managementDhyna Thorel, Saskia Ingen-Housz-Oro, Daniel Benaïm, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|February 2, 2023
Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patientsIngrid Costedoat, Martin Wallaert, Aurelie Gaultier, et al.American Journal of Ophthalmology|February 5, 2026
Adalimumab, Anakinra and Tocilizumab in patients with non-infectious Uveitis: A multicenter randomized controlled trialDavid Saadoun, Amine Ghembaza, Sarah Touhami, et al.Pageof 5